



## Procysbi® (cysteamine bitartrate) – New formulation approval

- On February 18, 2020, [Horizon Therapeutics announced the FDA approval](#) of [Procysbi \(cysteamine bitartrate\)](#) delayed-release oral granules, for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
- Procysbi was previously approved as a delayed-release oral capsule formulation. The granules and capsules share the same indication.
- Warnings and precautions for Procysbi include Ehlers-Danlos-like syndrome, skin rash, gastrointestinal ulcers and bleeding, central nervous system symptoms, leukopenia and/or elevated alkaline phosphatase levels, and benign intracranial hypertension.
- The recommended dose of Procysbi in cysteamine-naïve patients is weight-based. In patients switching from immediate-release cysteamine ([Cystagon®](#)) to Procysbi, start with a total daily dose of Procysbi equal to the previous total daily dose of immediate-release cysteamine bitartrate.
  - The Procysbi dose should be given every 12 hours.
  - The maximum dosage of Procysbi is 1.95 grams/m<sup>2</sup> of body surface area per day.
  - The oral granules should not be crushed or chewed. The granules should be sprinkled and mixed in applesauce, berry jelly or fruit juice (except grapefruit juice).
  - Refer to the Procysbi drug label for complete dosing and administration recommendations.
- Horizon Therapeutics plans to launch the oral granule formulation of Procysbi in the first half of this year. The new formulation will be available as 75 mg and 300 mg single-use packets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.